McKesson Corporation $MCK Position Boosted by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. lifted its stake in McKesson Corporation (NYSE:MCK) by 3.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,217 shares of the company’s stock after purchasing an additional 770 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in McKesson were worth $18,709,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. IAM Advisory LLC lifted its position in McKesson by 0.3% in the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after buying an additional 13 shares in the last quarter. PDS Planning Inc increased its stake in shares of McKesson by 1.1% in the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after acquiring an additional 13 shares during the last quarter. Cardinal Point Capital Management ULC raised its holdings in shares of McKesson by 2.2% during the second quarter. Cardinal Point Capital Management ULC now owns 645 shares of the company’s stock worth $473,000 after acquiring an additional 14 shares in the last quarter. Goldstein Advisors LLC boosted its position in McKesson by 4.4% during the third quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after purchasing an additional 14 shares during the last quarter. Finally, Warren Street Wealth Advisors LLC grew its stake in McKesson by 4.9% in the third quarter. Warren Street Wealth Advisors LLC now owns 319 shares of the company’s stock valued at $246,000 after purchasing an additional 15 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Trading Down 3.9%

NYSE MCK opened at $916.08 on Friday. McKesson Corporation has a 1 year low of $585.22 and a 1 year high of $971.93. The company has a fifty day simple moving average of $837.61 and a 200 day simple moving average of $785.95. The company has a market cap of $112.21 billion, a P/E ratio of 26.35, a P/E/G ratio of 1.53 and a beta of 0.40.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts forecast that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Activity at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares in the company, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on MCK shares. Evercore reiterated an “outperform” rating and set a $1,000.00 price target on shares of McKesson in a report on Thursday, November 6th. Morgan Stanley reiterated an “overweight” rating and issued a $966.00 target price on shares of McKesson in a research note on Thursday, January 29th. UBS Group boosted their target price on shares of McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. raised their price target on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Barclays started coverage on shares of McKesson in a research note on Monday, December 8th. They issued an “overweight” rating and a $960.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $937.07.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.